2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses the difference between clinical liquidity and financial liquidity.
P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses the difference between clinical liquidity and financial liquidity.
The Breakthrough Oncology Accelerator flagship program at Atlantic Health System was announced on October 4, 2018, of which the Translational Genomics Research Institute and Origin Commercial Ventures will be a part.
Smith, who is responsible for strategy and business development at Origin, says that financial liquidity is critical in unleashing clinical liquidity. Smith says that Origin is working very closely with the payer community, pharmaceutical companies, and the reinsurance and banking communities to create more shared performance models with payers.
This will help streamline the coordination that is required to bring novel therapies to patients, notes Smith. Now, Origin is in the process of building financial models that will enable a longer stream of payments, more performance-based payments, and more coordinated protocols and therapies between payers and clinicians. This will ensure that patients receive the therapy when they need it, practical onboarding of novel therapies, and incentive to pharmaceutical companies to bring more therapies to the table.